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Abstract 
Background: Trachoma, caused by ocular Chlamydia trachomatis, is the leading infectious cause of blindness world-
wide. Sudan first reported trachoma in the 1930s and has since been consistently endemic. Ocular C. trachomatis 
previously isolated from trachoma patients in Sudan in 1963 was antigenically identical to an isolate from Saudi Arabia 
(A/SA1). No contemporary ocular C. trachomatis whole genome sequences have been reported from Sudan.
Methods: This study sequenced twenty ocular C. trachomatis isolates to improve understanding of pathogen diver-
sity in North-East Africa and examine for genomic variation specific to Sudan, possibly related to the persistence of 
trachoma in surveyed communities. High quality, whole genome sequences were obtained from 12/20 isolates.
Results: All isolates were serovar A and had tarP and trpA sequences typical of classical, ocular C. trachomatis isolates. 
The Sudanese isolates formed a closely related subclade within the T2-trachoma clade of C. trachomatis phylogeny 
distinct from geographically disparate ocular isolates, with little intra-population diversity. We found 333 SNPs that 
were conserved in Sudanese ocular isolates but rare compared to other ocular C. trachomatis populations, which were 
focused in two genomic loci (CTA0172-CTA0173 and CTA0482).
Conclusions: Limited intra-population diversity and geographical clustering of ocular C. trachomatis suggests mini-
mal transmission between and slow diversification within trachoma-endemic communities. However, diversity may 
have been higher pre-treatment in these communities. Over-representation of Sudan-specific SNPs in three genes 
suggests they may have an impact on C. trachomatis growth and transmission in this population.
Keywords: Trachoma, Ocular, Chlamydia trachomatis, Genomics, Whole-genome sequencing
© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Chlamydia trachomatis is one of the most common 
sexually transmitted infections worldwide and the lead-
ing infectious cause of blindness. Trachoma, caused by 
ocular C. trachomatis infection, is targeted for elimina-
tion by 2020 [1]. Trachoma was first formally described 
in Sudan in the 1930s [2] and sporadic reports since then 
[3], including a review of records from 1959 to 1969 [4], 
indicated trachoma as a public health problem. In Sudan, 
the causative agent was first isolated from conjunctival 
scrapings in the 1960s and then again in the 1970s [5, 
6], with noted antigenic identity to an historical isolate 
from Saudi Arabia [7]. In 2011, approximately 100,000 
participants were surveyed across the northern states of 
Sudan [8]. This study identified 14/88 districts requir-
ing antibiotics, facial cleanliness and environmental 
improvement interventions for trachomatous inflamma-
tion, follicular (TF) and 20/88 districts requiring surgery 
intervention for trachomatous trichiasis (TT). Continued 
trachoma surveillance and community-level administra-
tion of azithromycin have since been undertaken by the 
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Sudanese Ministry of Health as part of the Global Tra-
choma Mapping Project.
Until recently, few complete genome sequences of ocu-
lar C. trachomatis have been available [9–11]. Reduced 
cost and improvements in technique [12–14] have seen 
a significant increase in whole-genome sequencing 
(WGS) of C. trachomatis; however, most studies have 
not investigated the relationship between sequence vari-
ation and clinical outcomes [15–21]. Studies that have 
examined this link have invariably focussed on urogeni-
tal isolates [22–24]. In 2018, we published a study from 
Bijagos Islands, Guinea-Bissau that used a genome-wide 
association study of 81 ocular C. trachomatis isolates to 
identify genomic markers of disease severity in trachoma 
[25]; this study suggested there is C. trachomatis genomic 
diversity within populations and that it may be linked to 
clinical outcomes.
Despite the high prevalence of trachoma, no studies 
have sequenced C. trachomatis isolates from Sudan. Tra-
choma was endemic in the Gadarif districts of Algalabat 
Eastern (TF: 19.8%; TT: 1.9%) and Alrahad (TF: 7.1%; 
TT: 4.8%) in 2011. Six and four mass annual rounds of 
azithromycin, respectively, have had limited impact on 
trachoma endemicity in these districts, according to the 
Global Trachoma Atlas (http://www.trach omaat las.org). 
A cross-sectional population-based survey was under-
taken in these districts to determine the prevalence of 
active trachoma and ocular C. trachomatis infection, 
as well as the burden of common, nasopharyngeal non-
chlamydial pathogens. This study sequenced twenty C. 
trachomatis isolates from the survey in these Sudanese 
trachoma-endemic districts to characterise ocular C. tra-
chomatis genomic diversity.
Methods
Study design and population
A descriptive cross-sectional population-based trachoma 
prevalence study was conducted to determine the preva-
lence of C. trachomatis and active trachoma (TF and/or 
trachomatous inflammation, intense [TI]) after multiple 
annual rounds of mass drug administration (MDA) with 
azithromycin. The studies were undertaken in Jarmai and 
Gargosha villages of Alrahad District and Alsaraf Alah-
mar (Bawi East, Bawi West, Bawi South and Bawi Centre) 
and Saraf Tabaldia villages of Algalabat Eastern District, 
Gadarif State during the period from November 2016 to 
April 2019. A total of 3529 children aged 1–9 years were 
examined for signs of active trachoma.
Trachoma clinical diagnosis
Examination for trachoma signs was conducted by oph-
thalmic medical assistants trained in the WHO simpli-
fied grading system. Each eye was examined for TF and 
TI. Both eyes were examined and findings for the worst 
affected eye recorded. Alcohol was used to clean the 
examiner’s fingers between examinations. Individuals 
with signs of active trachoma (TF and/or TI) were offered 
free treatment with antibiotics according to the national 
guidelines.
Sample collection and processing
Four-hundred and nine samples were collected from 
children clinically diagnosed as having active trachoma 
(TF and/or TI). Two conjunctival samples were collected 
from each participant by four passes of a Dacron polyes-
ter swab with a one-quarter turn between passes. Swabs 
were stored in UTM transport media (Thermo Fisher 
Scientific, Hemel Hempstead, UK) and stored at − 20 °C 
until processing. Total genomic DNA was extracted from 
samples using the G-spin Total DNA kit (iNtRON Bio-
technology, Seongnam, Korea).
Detection and quantitation of C. trachomatis
A previously validated assay [26, 27] targeting the highly 
conserved, C. trachomatis-specific genomic omcB was 
adapted for use in an end-point PCR to identify C. tra-
chomatis-positive samples. Chlamydial DNA from clini-
cal samples was amplified using a conventional PCR 
machine (SensoQuest, Gränningen, Germany), using 
Maxime PCR Pre Mix kit (iNtRON Biotechnology, 
Seongnam, Korea) and primers at 900 nM. Amplification 
was performed in 30 μl reaction volumes containing 2 μl 
of template DNA. Cycle conditions were as follows: 95 °C 
for 30 s, 59.9 °C for 30 s, 72 °C for 2 min. PCR products 
were subjected to agarose gel electrophoresis. A result 
was considered positive for C. trachomatis when a band 
of the size 106 bp was visible in the gel. Twenty C. tra-
chomatis-positive samples were further tested using an 
in-house, quantitative ddPCR assay. This assay quantifies 
both C. trachomatis plasmid and genome (omcB); C. tra-
chomatis load was defined as genome copies per µl.
Sequencing, processing and analysis of C. trachomatis
DNA was enriched using SureSelect C. trachomatis-spe-
cific baits and sequenced on the Illumina NextSeq plat-
form as previously described [20, 25]. Raw reads were 
trimmed and filtered using Trimmomatic [28]. Filtered 
reads were aligned to a reference genome (A/Har13) with 
Bowtie2 [29], variant calls were identified with SAM-
tools/BCFtools [30]. Multiple genome and plasmid align-
ments were generated using progressiveMauve, multiple 
gene alignments were generated using muscle. Phylog-
enies were computed using RaxML [31] and visualised in 
R. Domain structure of tarP and truncation of trpA were 
characterised as previously described [25]. Multi-locus 
sequences types (MLST) were determined from filtered 
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reads using stringMLST [32] and the hr-MLST-6 data-
base [33]. Minimum-spanning trees were constructed 
using BioNumerics 7.6 created by Applied Maths NV 
(http://www.appli ed-maths .com). The discriminatory 
power of the MLST types was evaluated using Simpson’s 
discriminatory index as previously described [34]. Pair-
wise nucleotide diversity was calculated as previously 
described [25]. ABRicate and the ResFinder database 
(https ://githu b.com/tseem ann/abric ate) were used to test 
for the presence of antimicrobial resistance genes.
Identification of polymorphisms associated with Sudanese 
origin
The Sudanese C. trachomatis isolates were compared to 
a global population of ocular isolates (n = 166 [15, 17, 20, 
21, 25]) to identify polymorphisms associated with Suda-
nese origin. Sites with a major allele frequency of < 0.8 
within the twelve Sudanese isolates and a frequency > 0.2 
of the Sudan-conserved alleles within the global popula-
tion were excluded. Annotations were transferred from 
the ocular reference genome A/Har13.
Results
Demographic information
Twenty C. trachomatis-positive samples of sufficient load 
by ddPCR quantitation of omcB load were available for 
whole-genome sequencing (WGS), from seven villages 
across two districts of Sudan (Additional file 1: Table S1). 
All individuals had TF of which 13/20 also had TI. Age 
and gender were not associated with concurrent TF and 
TI.
Sequencing results
Sequencing was successful for all 20 samples (Addi-
tional file 1: Table S2), a median of 1.87 × 106 reads were 
obtained (95% CI: 1.48 × 106–2.50 × 106). A median of 
3.73 ×  105 reads aligned to the reference genomes, A/
HAR-13 (95% CI: 0.09 × 105–17.84 × 105). Based on 
genome coverage of > 98% and a minimum read depth of 
10 there were twelve samples for post-sequencing analy-
sis. Chlamydia trachomatis infection load was generally 
lower in 8/20 samples that did not meet these quality 
control criteria (mean load 444 omcB copies/µl and 1861 
omcB copies/µl in excluded and included samples respec-
tively). However, two samples from this study with less 
than 50 omcB copies/µl returned high quality sequences, 
therefore load cannot completely explain sequencing 
quality. Median read depth of the twelve high quality 
sequences included in the post-sequencing analysis was 
308 (95% CI: 59.9–511.2).
Phylogenetic analysis
Phylogenetic analysis of the twelve whole-genome 
sequences placed them into a closely grouped sub-clade 
within the T2-trachoma clade (Fig.  1), the closest exist-
ing sequences were a sub-clade collected from the Bija-
gos Islands, Guinea-Bissau in 2012. Plasmid phylogeny 
showed similar close grouping of the isolates within the 
trachoma clade (Additional file 2: Figure S1).
All twelve sequences were ompA serovar A (Fig.  2). 
Seven polymorphic sites were present in ompA across 
nine sequences, leading to four amino acid changes 
(Table 1). Two sequences contained a single amino acid 
deletion. The closest related ompA sequences by blast+ 
alignment were A/SA1 (3/12) and A/HAR-13 (9/12).
MLST analysis, including ompA (hr-MLST-6), iden-
tified four novel sequence types (ST) with a Simpson’s 
discriminatory index of 0.67. A minimum spanning tree 
including all available ocular ST showed clustering of 
Sudanese isolates, with little evidence for village-level 
resolution (Fig.  3). Pairwise nucleotide diversity using 
WGS data was 0.0014. All sequences had tarP domain 
structure (four actin-binding domains and three tyros-
ine-repeat regions) and truncated trpA (531del) typical 
of ocular strains. One sequence had an insertion in trpA 
(115_116AG in B9) which led to an earlier truncation. 
There was no evidence for the presence of macrolide 
resistance alleles.
A comparison of the Sudanese sequences with 166 pre-
viously sequenced samples from trachoma-endemic com-
munities [15, 17, 20, 21, 25] identified genomic markers 
specific to Sudan. After filtering, 333 single nucleotide 
polymorphisms (SNPs) across 178 sequences were found 
to be conserved in Sudan (allele frequency ≥ 0.8) and rare 
in the global population (allele frequency ≤ 0.2). SNPs 
were dispersed throughout the genome, with two foci 
in the genes CTA0164-CTA0179 and CTA482-CTA499 
(Fig.  4). Within these focal regions, CTA0482 (D/UW3; 
CT442) contained 19 SNPs, CTA0172 and CTA0173 (D/
UW3; both CT163) contained 20 SNPs. A further cluster 
Fig. 1 Maximum likelihood reconstruction of whole genome phylogeny of ocular Chlamydia trachomatis sequences from Sudan. Whole genome 
and plasmid phylogeny of 12 C. trachomatis sequences from Sudan and 188 Ct clinical and reference strains. Sudanese C. trachomatis sequences 
were mapped to C. trachomatis A/HAR-13 using Bowtie2. SNPs were called using SAMtools/BCFtools. Phylogenies were computed with RAxML 
from a variable sites alignment using a GTR + gamma model and are midpoint rooted. The scale-bar indicates evolutionary distance. Sudanese C. 
trachomatis sequences generated in the present study are coloured green, and reference strains are coloured by tissue localization (blue, ocular; 
yellow, urogenital; purple, LGV)
(See figure on next page.)
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of SNPs was located between CTA_0777 and CTA_0801, 
the SNPs in this region were not overrepresented in any 
individual gene.
Discussion
This study successfully sequenced twelve recent ocular 
C. trachomatis samples from a trachoma-endemic region 
of Sudan with no prior characterisation of chlamydial 
genomics. All sequences were phylogenetically within 
the T2-trachoma clade and contained ompA, tarP and 
trpA sequences typical of classical ocular strains. The 
Sudanese sequences were phylogenetically distinct from 
trachoma sequences collected in geographically dispa-
rate sites. This study found 333 alleles conserved within 
Sudan and rare within the global ocular C. trachoma-
tis population were focussed in two distinct genomic 
regions. There was no evidence of macrolide resistance 
alleles in the C. trachomatis population.
All sequences were genovar A by ompA typing with 
a high level of conservation, historically this has been 
the most prevalent ocular ompA type in sub-Saharan 
Africa [15, 25, 35–37]. Whilst three quarters of non-
synonymous SNPs in ompA were within surface-exposed 
domains, none were within reported antigenic sites 
[38–44]. Sequence variation in tarP and the trypto-
phan operon are also ocular clade-specific. There were 
ten unique tarP sequences in this population, all coded 
for the domain structure typical of ocular isolates, spe-
cifically four actin-binding domains and three tyrosine-
repeat regions [45]. The sequence of trpA was highly 
conserved, 11 out of 12 identical sequences had a trun-
cating deletion and one had a truncating insertion. 
Therefore, all of the Sudanese sequences had a non-
functional tryptophan operon, thought to be restrictive 
to growth in the urogenital tract [46, 47]. These features 
and branching of the Sudanese sequences within the clas-
sical T2-trachoma clade suggests they are typical ocular 
strains. Results of the comparison to a global population 
of C. trachomatis sequences, aimed at identifying Sudan-
specific polymorphisms, supported this assertion. Only 
333 alleles conserved within Sudan and rare within the 
global population were found, of which only two were 
unique to the Sudanese sequences. Two genes, CTA0172-
CTA0173 and CTA0482, harboured > 10% of these alleles. 
Both encoded proteins have been associated with lipid 
droplets in C. trachomatis-infected cells in vitro, target-
ing of which is thought to enhance C. trachomatis sur-
vival and replication [48, 49]. It is possible that altered 
expression or activity of these genes may impact the 
growth and survival of these Sudanese ocular strains.
Pairwise nucleotide diversity is a measure of the extent 
of polymorphism within a population, a higher value 
indicating increased polymorphism. Pairwise diversity 
reported from studies of ocular C. trachomatis from dif-
ferent trachoma-endemic communities has produced 
contrasting results, with those sequences originating 
directly from ocular swabs being significantly more 
variable at the population level than those derived from 
repeatedly passaged cultured isolates. The pairwise diver-
sity in this population was 0.0014, which is higher than 
isolates from Rombo, Tanzania [50] but lower than found 
in the Bijagos Islands, Guinea-Bissau [51]. This supports 
our previous assertion that in vitro passage of isolates 
prior to sequencing, influences sequence diversity. This 
suggests that in the future, when possible, C. trachoma-
tis samples should be sequenced directly from clinical 
samples.
MLST analysis has been evaluated extensively in uro-
genital C. trachomatis, with evidence suggesting it may 
be a useful tool for determining diversity in a population 
[52]. Only one study has investigated its utility in ocu-
lar C. trachomatis and it focussed on a small number of 
strains [53], primarily historical reference isolates. Our 
study identified five novel sequence types. Simpson’s 
discriminatory index, which calculates the probability of 
two randomly sampled strains in a population being the 
same ST, has been used to evaluate the discriminatory 
power of MLST schemes. The five novel ST identified in 
this study had a discriminatory index of 0.67, consider-
ably below the suggested threshold of 0.90 for high con-
fidence that the typing system is of sufficient resolution 
[34]. This was supported by close clustering and overlap 
of ST between villages from separate districts. The dis-
criminatory index for Sudanese samples is slightly less 
than that calculated from a global population of trachoma 
isolates (0.772) and considerably lower than that for a 
global population of urogenital isolates (0.968) [53]. This 
is unsurprising as the metric was designed for “large and 
representative (nonlocal) collections of distinct strains” 
[34]. The MLST scheme applied in this analysis, which 
(See figure on next page.)
Fig. 2 Maximum likelihood reconstruction of ompA phylogeny of ocular Chlamydia trachomatis sequences from Sudan. Phylogeny of ompA from 
12 C. trachomatis sequences from Sudan and 188 C. trachomatis clinical and reference strains. Sudanese C. trachomatis sequences were mapped 
to C. trachomatis A/HAR-13 using Bowtie2. SNPs were called using SAMtools/BCFtools. Phylogenies were computed with RAxML from a variable 
sites alignment using a GTR + gamma model and are midpoint rooted. The scale-bar indicates evolutionary distance. Sudanese C. trachomatis 
sequences generated in the present study are coloured green, and reference strains are coloured by tissue localization (blue, ocular; yellow, 
urogenital; purple, LGV)
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Table 1 Identified ompA polymorphisms
Abbreviation: na, the polymorphism did not lead to an amino acid change and therefore did not affect any region of the protein
Sequences affected Nucleotide change Amino acid change Protein region
B1, J52 305C>T na na
A8 349G>A D117N Surface exposed
B1, J52 736A>G na na
T94, TF16, TF34 743C>T A248V Surface exposed
J52 1000T>G S334A Membranous
B13 1007A>G T337A Surface exposed
A8, TF54 1007_1009del na na
TF34 1011A>C na na
Fig. 3 Minimum spanning tree of hr-MLST-6 types of Chlamydia trachomatis sequences from Sudan. Twelve C. trachomatis sequences from Sudan 
and 136 ocular C. trachomatis clinical and reference strains were used to construct a minimum spanning tree of hr-MLST-6 types. Multi-locus 
sequence types were determined using stringMLST. Minimum spanning trees were constructed using BioNumerics 7.6. Sudanese sequence types 
are coloured by village of origin, clinical and reference strains are coloured by country of origin
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targets five non-housekeeping genes and approximately 
half of the sequence of ompA, provided lower resolution 
in this case than full-length ompA alone (discrimina-
tory index of 0.773). High levels of recombination in and 
around ompA has led others to suggest it is an unsuitable 
target for molecular epidemiological characterisation of 
C. trachomatis isolates [17], supporting the greater use of 
WGS and need for exploration of novel MLST systems.
Considering the lack of diversity within the Sudanese 
sequences, the clear phylogenetic separation from geo-
graphically disparate populations of ocular C. trachoma-
tis whole genome sequences is striking. This mirrors 
previous findings from Guinea-Bissau [25], Tanzania [17] 
and the Solomon Islands [20], suggesting this geographi-
cal clustering of sequences is a common feature of ocu-
lar C. trachomatis. The sequences from Guinea-Bissau 
(beginning with 11151, 13108 or 9471) are the largest 
published collection of ocular C. trachomatis yet still split 
into only two sub-clades, one of which branched phylo-
genetically close to the C. trachomatis sequenced in this 
study. The close relatedness of the Sudanese sequences, 
collected in 2018, to an isolate collected in Saudi Ara-
bia in 1957 (A/SA1) is even more remarkable. A similar 
phylogenetic relatedness was found for two isolates col-
lected in The Gambia over 20 years apart (B/Jali-20 and 
B-M48). These findings suggest slow and geography-
related diversification of ocular C. trachomatis, with lit-
tle evidence of transmission between geographically 
separate trachoma-endemic communities. This may 
be because C. trachomatis is a successful, well-adapted 
pathogen requiring little further adaptation to maintain 
within a population or that country/region-specific pres-
sures may be driving adaptation. It is also possible that 
diversity of C. trachomatis in these regions of Sudan had 
been reduced by prior mass community-level treatment. 
Although, despite repeated rounds of treatment and con-
sistent with previous studies, no evidence of macrolide 
resistance was found in this population. This supports 
results from ompA typing of C. trachomatis samples pre- 
and post-treatment that found no difference in diversity 
[54].
Thus far no study has published whole-genome 
sequence data from ocular C. trachomatis samples col-
lected pre- and post-treatment in the same community. 
However, studies of ocular C. trachomatis sequences 
have found no change in azithromycin susceptibility after 
Fig. 4 Single nucleotide polymorphisms on the Chlamydia trachomatis genome specific to Sudan (n = 333). Single nucleotide polymorphisms 
conserved in Sudan (allele frequency ≥ 0.8) and rare in other C. trachomatis isolates (allele frequency ≤ 0.2) were identified by comparing these C. 
trachomatis sequences (n = 12) to ocular isolates from other populations (n = 166). Two loci (CTA0172-CTA0173 and CTA0482) which harboured the 
majority of Sudan-specific alleles are indicated (blue boxes)
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treatment [55–57]. This supports the absence of mac-
rolide resistance genes in our sequences from Sudan. 
Azithromycin is known to effectively clear infections 
at the individual level, but ocular C. trachomatis often 
persists in communities even after multiple rounds of 
treatment [58, 59]. This is likely due to a combination 
of factors, including baseline levels of infection, envi-
ronmental improvements and treatment coverage. It is 
possible that genomic factors may support continued 
transmission of C. trachomatis after treatment, even in 
the absence of genes that directly inhibit macrolide activ-
ity. Genes with critical functions that promote C. tra-
chomatis survival and replication may lead to a higher 
pre-treatment load of infection, reducing the likelihood 
of complete clearance, or enhance emergence of post-
treatment residual infections. Additionally, there is the 
possibility of indirect resistance in which a resistant pop-
ulation of bacteria can provide protection for a suscepti-
ble population [60].
Conclusions
This first WGS study of ocular C. trachomatis from 
trachoma-endemic regions of Sudan identified typical 
T2-trachoma isolates with low intra-population diversity 
and remarkable similarity to a reference C. trachoma-
tis strain collected in Saudi Arabia 60 years previously. 
There was no evidence of macrolide resistance alleles in 
our C. trachomatis sequences from post-treatment com-
munities, however, two foci of polymorphism specific to 
these populations were identified. A greater sample size 
and pre-treatment samples are required to reliably inves-
tigate if genomic diversity is related to population treat-
ment success. The phylogenetic clustering of sequences 
by country of collection warrants further investiga-
tion to understand the evolutionary history of ocular C. 
trachomatis.
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